Cryolife (NYSE:CRY) & Orthopediatrics (NYSE:KIDS) Critical Analysis

Cryolife (NYSE:CRY) and Orthopediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Risk and Volatility

Cryolife has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Orthopediatrics has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cryolife and Orthopediatrics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cryolife $262.84 million 4.14 -$2.84 million $0.26 112.00
Orthopediatrics $57.56 million 10.24 -$12.02 million ($0.96) -41.83

Cryolife has higher revenue and earnings than Orthopediatrics. Orthopediatrics is trading at a lower price-to-earnings ratio than Cryolife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cryolife and Orthopediatrics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cryolife -0.09% 3.79% 1.81%
Orthopediatrics -16.71% -16.43% -10.61%

Institutional and Insider Ownership

71.2% of Cryolife shares are held by institutional investors. Comparatively, 48.7% of Orthopediatrics shares are held by institutional investors. 4.4% of Cryolife shares are held by insiders. Comparatively, 40.7% of Orthopediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Cryolife and Orthopediatrics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cryolife 0 1 2 0 2.67
Orthopediatrics 0 0 4 0 3.00

Cryolife currently has a consensus target price of $32.22, suggesting a potential upside of 10.63%. Orthopediatrics has a consensus target price of $39.33, suggesting a potential downside of 2.06%. Given Cryolife’s higher probable upside, analysts plainly believe Cryolife is more favorable than Orthopediatrics.

Summary

Cryolife beats Orthopediatrics on 10 of the 14 factors compared between the two stocks.

About Cryolife

CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft system for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard. It offers trauma and deformity procedures; scoliosis procedures for the treatment of spinal deformity; and sports medicine procedures. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2007 and is headquartered in Warsaw, Indiana.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.